The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

被引：34

作者：

Dimopoulos, Meletios Athanasios

Kastritis, Efstathios

Delimpassi, Sossana ^{[1
]}

Zomas, Athanasios ^{[2
]}

Kyrtsonis, Marie Christine ^{[3
]}

Zervas, Konstantinos ^{[4
]}

机构：

[1] Evangelismos Med Ctr, Dept Hematol, Thessaloniki, Greece

[2] Attikon Univ Hosp, Thessaloniki, Greece

[3] Univ Athens, Laikon Hosp, Dept Hematol, Thessaloniki, Greece

[4] Theagen Hosp, Dept Hematol, Thessaloniki, Greece

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷 / 09期

关键词：

D O I：

10.3324/haematol.12846

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1420 / 1422

页数：3

共 12 条

[1] Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Anagnostopoulos, A ;

Zervas, C ;

Kyrtsonis, MC ;

Zomas, A ;

Bourantas, C ;

Anagnostopoulos, N ;

Pangalis, G .

CLINICAL LYMPHOMA, 2005, 5 (04) :270-272

[2] Diagnosis and management of Waldenstrom's macroglobulinemia [J].

Dimopoulos, MA ;

Kyle, RA ;

Anagnostopoulos, A ;

Treon, SP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1564-1577

[3] Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide [J].

Dimopoulos, Meletios Athanasios ;

Anagnostopoulos, Athanasios ;

Kyrtsonis, Marie-Christine ;

Zervas, Konstantinos ;

Tsatalas, Constantinos ;

Kokkinis, Garyfallia ;

Repoussis, Panagiotis ;

Symeonidis, Argyris ;

Delimpasi, Souzana ;

Katodritou, Eirini ;

Vervessou, Elina ;

Michali, Evridiki ;

Pouli, Anastasia ;

Gika, Dimitra ;

Vassou, Amalia ;

Terpos, Evangelos ;

Anagnostopoulos, Nikolaos ;

Economopoulos, Theophanis ;

Pangalis, Gerasimos .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3344-3349

[4] PROGNOSTIC FACTORS IN WALDENSTROM MACROGLOBULINEMIA - A REPORT OF 167 CASES [J].

FACON, T ;

BROUILLARD, M ;

DUHAMEL, A ;

MOREL, P ;

SIMON, M ;

JOUET, JP ;

BAUTERS, F ;

FENAUX, P .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1553-1558

[5] Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases [J].

García-Sanz, R ;

Montoto, S ;

Torrequebrada, A ;

de Coca, AG ;

Petit, J ;

Sureda, A ;

Rodríguez-García, JA ;

Massó, P ;

Pérez-Aliaga, A ;

Monteagudo, MD ;

Navarro, I ;

Moreno, G ;

Toledo, C ;

Alonso, A ;

Besses, C ;

Besalduch, J ;

Jarque, I ;

Salama, P ;

Rivas, JAH ;

Navarro, B ;

Bladé, J ;

Miguel, JFS .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :575-582

[6] Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia [J].

Ghobrial, IM ;

Fonseca, R ;

Gertz, MA ;

Plevak, MF ;

Larson, DR ;

Therneau, TM ;

Wolf, RC ;

Hoffmann, RJ ;

Lust, JA ;

Witzig, TE ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Zeldenrust, SR ;

Greipp, PR ;

Kyle, RA .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (02) :158-164

[7] STUDY OF PROGNOSIS IN WALDENSTROMS MACROGLOBULINEMIA - A PROPOSAL FOR A SIMPLE BINARY CLASSIFICATION WITH CLINICAL AND INVESTIGATIONAL UTILITY [J].

GOBBI, PG ;

BETTINI, R ;

MONTECUCCO, C ;

CAVANNA, L ;

MORANDI, S ;

PIERESCA, C ;

MERLINI, G ;

BERTOLONI, D ;

GRIGNANI, G ;

POZZETTI, U ;

CAPORALI, R ;

ASCARI, E .

BLOOD, 1994, 83 (10) :2939-2945

[8] Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia [J].

Kyle, RA ;

Treon, SP ;

Alexanian, R ;

Barlogie, B ;

Björkholm, M ;

Dhodapkar, M ;

Lister, TA ;

Merlini, G ;

Morel, P ;

Stone, M ;

Branagan, AR ;

Leblond, W .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :116-120

[9] Prognostic factors in symptomatic Waldenstrom's macroglobulinemia [J].

Merlini, G ;

Baldini, L ;

Broglia, C ;

Comelli, M ;

Goldaniga, M ;

Palladini, G ;

Deliliers, GL ;

Gobbi, PG .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :211-215

[10]

Morel P, 2000, BLOOD, V96, P852

← 1 2 →